SLC5A2 and chronic kidney disease: EMPA-KIDNEY (NCT03594110): following the success of previous SGLT2 inhibitor trials, the EMPA-KIDNEY trial has shown that empagliflozin significantly reduces the risk of CKD progression and cardiovascular mortality [183].